Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.580
-0.140 (-3.76%)
At close: Jul 31, 2026, 4:00 PM EDT
3.590
+0.010 (0.28%)
After-hours: Jul 31, 2026, 7:59 PM EDT

Fulcrum Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--802.816.3419.16
Revenue Growth
--2752.05%-55.77%-66.91%117.19%
Gross Profit
--802.816.3419.16
Operating Income
-96.05-84.77-21.9-110.66-112.56-81.05
Net Income
-19.6-74.88-9.73-97.34-109.87-80.85
Earnings Per Share
-1.21-1.18-0.16-1.59-2.44-2.29
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
318.84352.31241.02236.22202.92218.16
Total Debt
5.286.448.6310.8213.420
Net Cash (Debt)
313.56345.86232.39225.4189.5218.16
Net Cash Growth
51.82%48.83%3.10%18.95%-13.14%93.21%
Net Cash Per Share
4.475.463.753.684.216.17

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-65.78-60.07-2.22-90.97-97.05-78.48
Capital Expenditures
-0.37-0.31-0.28-0.51-1.96-1.71
Free Cash Flow
-66.14-60.38-2.5-91.47-99.01-80.19
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--100.00%100.00%100.00%100.00%
Operating Margin
---27.37%-3945.24%-1774.85%-422.97%
Pretax Margin
---12.16%-3470.05%-1732.43%-421.89%
Profit Margin
---12.16%-3470.05%-1732.43%-421.89%
FCF Margin
---3.12%-3261.07%-1561.23%-418.47%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
--3.17148.9959.8037.50